Chronic medication use may increase in breast cancer survivors after cancer treatment
the ONA take:
Researchers report an increase in breast cancer survivor’s use of chronic medication after cancer treatment. The study was published online ahead of print in the journal Supportive Care in Cancer.
For the study, researchers sought to characterize the patterns of medication use by survivors of early-stage breast cancer from diagnosis to 1 year after chemotherapy.
Researchers enrolled 107 patients diagnosed between December 2011 and June 2014, all participants were treated at a single center. Medication use data was retrieved from prescription databases and records from the National Electronic Health Records.
Results showed that 46.7% of participants developed non-cancer comorbidities, including hypertension, hyperlipidemia, and diabetes.
The most common chronic medication types before chemotherapy were calcium channel blockers and lipid-modifying agents. Their use persisted during and after chemotherapy. The most commonly used post-chemotherapy medication was hormonal therapy.
Researchers found that there was a statistically significant increase in the average number of chronic disease medication classes prescribed to patients between the pre-chemotherapy and chemotherapy periods, as well as between the chemotherapy and post-chemotherapy periods (P < 0.0001).
“This study provides important insights into the design of medication management programs tailored to this population. Future studies should incorporate a control population to improve the interpretation of study results,” the authors concluded.
Researchers report an increase in breast cancer survivor’s use of chronic medication after cancer treatment.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|